We will begin reporting progress against our new commitments in our 2013 Corporate Responsibility report. Our forward-looking commitments around Health for all are:

• Adapt the open innovation R&D model, currently used for diseases of the developing world, to apply to other areas of great unmet medical need and scientific challenge, including infectious disease and Alzheimer’s disease, by 2015.
• Invest in the development of vaccines that don’t require continuous refrigeration, making distribution easier and less expensive.
• Continue to build a core range of products and formats to better meet the needs of people across the globe, including those less able to access and afford our products.
• Further embed our flexible pricing strategy and innovative business models for our prescription medicines and vaccines, to increase usage among those less able to access and afford our products.
• Continue to invest in innovative cross-sector partnerships to reduce child mortality.
• Continue to work with partners to support the strengthening of healthcare infrastructure. We anticipate this could improve access to healthcare for 20 million under-served people by 2020 (vs 2012).
• Through ViiV Healthcare, continue to increase access to our medicines and care for adults and children living with HIV around the world. We will help WHO and UNAIDS achieve their goal of reaching 15 million people globally with antiretroviral treatment by 2015.
• Build on our 30-year commitment to contribute to the fight against malaria through continued R&D investment and partnerships on the ground.
• Help eliminate and control ten neglected tropical diseases that affect 1.4 billion people, by 2020 – including the elimination of lymphatic filariasis, through our continued investment in R&D, ongoing product donations and our contribution to the London Declaration on Neglected Tropical Diseases.
• Continue to support the WHO objective of eradicating polio by 2018 by providing vaccines to UNICEF until this is achieved.